Market Newsdesk

VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has recently received approximately $600,000 CDN in the form of a refundable tax credit from its clinical research work in Australia. The expenses being refunded are from the Company’s Ifenprodil IPF and chronic cough Phase 2 clinical study program. Since the Phase 2 trial is still in progress, the company plans to submit additional eligible expenses for reimbursement from the tax refund program, in due course.

“Algernon’s unique business model of drug repurposing includes conducting as much clinical research as possible in Australia in order to take advantage of the Australian Government’s 41% refundable tax credit program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This refund, while expected, is an important part of our capital efficient R&D plan to drive value for our shareholders by keeping our research costs to an absolute minimum as we conduct early clinical investigations into the efficacy of our re-purposed compound targets.”

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
[email protected]
[email protected]
www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release


.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Des Moines, Nov. 16, 2020 (GLOBE NEWSWIRE) — LCS announces EverSafe 360°, a comprehensive program that sets the new standard for senior living and reimagines the way communities managed by LCS live and work together. This innovative program raises the bar in overall senior safety.

LCS created EverSafe 360⁰ as the next evolution in the endless pursuit of elevating the total resident experience.

As the nation’s second-largest operator in senior living, the health and safety of residents have always been the top priority for LCS. These past months have identified a greater need for a comprehensive approach to caring for residents and LCS has responded.

EverSafe 360° provides additional health, safety and security to residents, family and staff. It utilizes science-based practices that focus on the many facets of environmental care, including deep cleaning and state-of-the-art indoor air quality systems.

EverSafe 360° has established the LCS Medical Advisory Board that brings together a group of talented physicians who specialize in infectious diseases, mental health geriatrics and epidemiology. This team of experts will provide communities managed by LCS with real-time guidance to ensure the security and safety of all residents and staff.

Telemedicine technology will be deployed in all senior living communities to provide an overall health and wellness platform to assure residents in all levels of care have ready access to on-demand physician services. Telemedicine will provide increased opportunities for residents to receive medical care during a pandemic including, but not limited to, physician visits, therapy services, non-emergent assessments and post-acute physician follow up.

EverSafe 360° is all-encompassing and focuses on the emotional and physical aspects of keeping everyone as safe as possible to enjoy their “best life” experience at an LCS community. The program is delivered with the care and compassion that allows LCS to quickly and comprehensively help alleviate any concern around safety measures. 

The health and safety of 40,000 residents and 30,000 employees are our priorities. And with EverSafe 360°, LCS has raised the bar for senior living.

For more information about EverSafe 360°, click here.

About LCS

Established in 1971, LCS is a pioneer in the senior living industry and the nation’s second-largest operator. The LCS Family of Companies focuses on development, operations management, marketing and sales management, and strategic planning for Life Plan Communities, and rental independent living, assisted living, and memory care communities across the United States. The company also provides a full-service real estate private equity enterprise, insurance, national purchasing consulting services and in-home care. The LCS Family of Companies is committed to serving seniors and ensuring the best resident experience possible by working with partners to tailor and streamline solutions. In the field of senior living, Experience is Everything. For more information, visit LCSnet.com.

Pat Howard
LCS
5158837938
[email protected]

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020.

Brickell’s Chief Executive Officer, Robert Brown, will present a corporate overview and Brickell’s management team will be available for one-on-one meetings. The pre-recorded presentation will be available on the event website prior to the dates of the conference. A replay of the corporate presentation will be available in the investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations and will remain archived there for approximately 90 days.

About Sofpironium Bromide

Sofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide is currently being evaluated in a U.S. pivotal Phase 3 clinical program for the treatment of primary axillary hyperhidrosis and is approved (pending launch) in Japan for the same indication, under the brand name ECCLOCK^®.  Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.

About Hyperhidrosis

Hyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis^1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^® and Juvederm^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.                                

¹ Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.
² Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.

Brickell Investor Contact:

Dan Ferry
LifeSci Advisors
(617) 430-7576
[email protected]

ORLANDO, Fla., Nov. 16, 2020 (GLOBE NEWSWIRE) — Sustainable Green Team, Ltd. (OTC: SGTM) (“SGTM” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, engages Anthony L.G., PLLC to initiate FORM-10 process to become fully reporting, uplist, and assist with all SEC legal matters. This engagement was made shortly after the Company’s wholly owned subsidiary, Mulch Manufacturing expanded its 2021 mulch contracts with Circle K convenient stores, a subsidiary of Alimentation Couche-Tard, Inc. (OTC: ANCUF) (“ANCUF”).

After completing and posting the Company’s two year audit for years ending December 2018 and 2019 at the end of October, and 3rd quarter ending September 30, 2020 last week, the company is positioned and ready commence the FORM-10 process with its new highly referred firm, Anthony L.G. PLLC.

SGTM’s CEO and Director Tony Raynor states, “We have communicated with many firms since our audit completion to see whom would be best suited for our team, shareholders, and transpire our vision. After communicating with Laura Anthony and doing our due diligence, our team feels more confident then ever on achieving our ultimate goal to be listed on the NASDQ to maximize exposure and greater value.”

Anthony L.G. PLLC, is a comprehensive corporate, securities, and business transactional law firm. With a team of experienced attorneys to ensure that all aspects of corporate legal needs are satisfied whether completing an initial public offering, follow on offering, private placement, merger or acquisition or general business contracts and ongoing corporate maintenance. As the securities industry’s premier corporate and transactional law firm. 
To learn more please visit: http://www.anthonypllc.com

About Sustainable Green Team, Ltd. (SGTM)

Sustainable Green Team, Ltd. (“SGTM”), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The Company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The Company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The Company’s customers include governmental, residential and commercial clients.

SGTM currently has two wholly owned subsidiaries to efficiently asses areas, recover, manufacture, and distribute:

National Storm Recovery, LLC

National Storm Recovery, LLC (“NSR”), is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The Company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.

Central Florida Arborcare (“CFA”), a DBA of NSR has spent more than 40 years perfecting their technique for proper tree care, removal, and services. From tree removal, stump grinding, tree care, grapple hauling, and storm recovery, CFA ensures properties remain safe and businesses can continue as usual.
To learn more please visit: https://www.centralfloridaarborcare.com

Mulch Manufacturing, Inc.

Mulch Manufacturing, Inc. (“MMI”), being vertically integrated receiving large volume of wood fiber recovered from Central Florida Arborcare to feed raw material needs, MMI has the product line and distribution system to address a substantial customer base which can be expanded.
To learn more please visit: https://mulchmfg.com

For additional information regarding SGTM’s operations, expansion plans and production facilities, view the Company’s presentation.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions, are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any matter whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.

Company Contact:

Anthony Raynor
CEO & Director
407.886.8733 Office

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’ innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with viral nucleic acid including cccDNA transcription, providing a strong complement to Assembly Bio’s current portfolio.

Under the terms of the agreement, Door Pharmaceuticals will build upon its previous efforts to lead and conduct new discovery research, which will be funded by Assembly Bio. In return for an up-front payment and success-based milestones and royalties, Assembly Bio will be granted an exclusive option to license compounds arising from the collaboration and will be responsible for the continued development and commercialization of optioned compounds. Financial details were not disclosed.

“Door Pharmaceuticals was established by our co-founder, Adam Zlotnick, whose research led to the successful discovery of the core inhibitor candidates that comprise Assembly Bio’s clinical program,” said William Delaney, PhD, Chief Scientific Officer, Virology of Assembly Biosciences. “Adam is a true innovator, and this collaboration is a natural continuation of our work together. We’re excited to build upon our current pipeline of HBV core inhibitors with additional contributions from a science-driven company that shares our passion and focus for bringing new treatment options to patients facing HBV.”

“I’m thrilled at the opportunity to once again contribute to the advancement of Assembly Bio’s core inhibitor platform under this new collaboration,” said Adam Zlotnick, PhD, Founder of Door Pharmaceuticals. “There is a clear mechanistic rationale for the potential role that core inhibitors can play in the treatment of HBV, and it is our hope and belief that the complementary mechanisms of action of these core protein modulators will offer an important therapeutic pathway towards HBV cure.”

About HBV

Chronic hepatitis B virus (HBV) infection is a debilitating disease of the liver that afflicts over 250 million people worldwide with up to 90 million people in China, as estimated by the World Health Organization. HBV is a global epidemic that affects more people than hepatitis C virus (HCV) and HIV infection combined—with a higher morbidity and mortality rate. HBV is a leading cause of chronic liver disease and need for liver transplantation, and up to one million people worldwide die every year from HBV-related causes.

The current standard of care for patients with chronic HBV infection is life-long suppressive treatment with medications that reduce, but do not eliminate, the virus, resulting in very low cure rates. There is a significant unmet need for new therapies to treat HBV.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly Bio’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

About 
Door Pharmaceuticals

Door Pharmaceuticals was founded in 2018 by leading HBV researcher, Adam Zlotnick, PhD, a professor of molecular and cellular biochemistry at Indiana University; he is also a fellow of the American Academy of Microbiology and of the AAAS. The company is focused on research of virus structural proteins to discover new classes of inhibitors. The company is initially focused on HBV, with the vision to realize the potential for novel therapeutics for other viruses.

Forward-Looking Statements

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: the Door collaboration may not yield any novel assets and we may not exercise our option with respect to any collaboration compounds; Assembly Bio’s ability to initiate and complete clinical trials involving its HBV therapeutic product candidates in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; Assembly Bio may not observe sustained virologic response in patients who stop therapy in Study 211; Assembly Bio’s ability to maintain financial resources necessary to continue its clinical trials and fund business operations; any impact that the spread of the coronavirus and resulting COVID-19 pandemic may have on Assembly Bio’s business and operations, including initiation and continuation of its clinical trials or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Assembly Biosciences, Inc.
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
[email protected]

Media Contact
Sam Brown Inc.
Audra Friis
(917) 519-9577
[email protected]

Panel to be Held on Wednesday, November 18
th
at 5:00 PM ET

NEW YORK, NY, Nov. 16, 2020 (GLOBE NEWSWIRE) — via NewMediaWire ‒ PCG Advisory, Inc., a leading New York City-based investor relations and digital strategies firm, today announced that CEO Jeff Ramson will join a panel at the Virtual Fall Investor Summit taking place on November 16- 18, 2020. 

The panel, “Making Smart Investment Decisions in Uncertain Times,” will take place on Wednesday, November 18th at 5:00 PM ET. Other panelists include Shree Viswanathan, founder of SVN Capital and Steve Kiel, founder and CIO of Arquitos Capital. The panel will be moderated by Vijay Chopra, Portfolio Manager, DCM Advisors, LLC.

“In these uncertain and fast changing times, I look forward to this discussion with my fellow panelists as we all continue to search for successful investment strategies,” Ramson said. “At PCG we have a long history of identifying hidden strength and value in smaller cap stocks with the potential to perform well in various market environments.” 

For more information about the Virtual Fall 2020 Investor Summit, which offers free admission for investors as attendees, go to:
https://fall-investor-summit2020.events.issuerdirect.com/login

About PCG Advisory, Inc.

PCG Advisory is a leading investor relations firm dedicated to the delivery of top-tier strategic services that encompass investor relations, capital markets navigation, and corporate communications for innovative and emerging companies from around the globe. PCG Advisory has extensive experience with life sciences, technology and other emerging growth companies.

PCG Advisory is part of PCG Holdings Inc. PCG Holdings also owns Proactive Capital Group LLC., which manages a global macro hedge fund called Proactive Capital Partners, LP.  The fund invests in a broad spectrum of financial instruments, including an allocation for emerging public companies.

Contact:

Stephanie Prince
Managing Director
(646) 762-4518
[email protected]

SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Enview, a pioneer in the scalable processing of 3D geospatial data, has experienced considerable momentum on the heels of its recent launch of Enview Explore. The powerful web application leverages AI and cloud computing to automatically process 3D data at unprecedented speed and scale, making it an invaluable tool for the U.S. Air Force.

The company was recently selected by the Commander of Pacific Air Forces (COMPACAF) for award of a Phase III SBIR contract to deploy Enview’s Geospatial AI platform in support of air bases throughout Indo-Pacific Command (INDOPACOM). Phase III contracts are not easily won as they denote technologies ready for operational use rather than dollars earmarked for research and development.

“This is particularly exciting for us as we’ve worked hard to deliver throughout the R&D stages of the SBIR process. Being able to support operational end-users is a core focus for us, and this Phase III contract allows us to do just that,” said Enview CEO San Gunawardana.

Enview recently joined USAF Advanced Battle Lab (ABL) personnel at Nellis Air Force Base to deploy Enview Explore at the Advanced Battle Management System (ABMS) Onramp 2 exercise.

“We were thrilled to have the opportunity to demonstrate the power of Enview Explore in the field during this exercise. Of particular excitement was witnessing LiDAR data being streamed to the ground as it was being collected. Within 35 minutes of the initial collect, we were able to process and visualize the data through Explore’s 3D common operating picture,” said John Dombzalski, VP of Public Sector at Enview. “Shortly thereafter, Explore automatically identified changes to terrain, buildings, and vehicles in support of runway damage assessment and search and rescue operations. When all was said and done, the near-real time change analysis concluded before the plane even landed. We’re excited to see how this level of speed and fidelity enhances agile combat employment and enables multi-domain battle managers to make more rapid and precise decisions.”

Enview was previously awarded an Air Force Phase II SBIR to automatically exploit airborne LiDAR for the purpose of route-navigation determination and infrastructure assessment for Air Force Special Operations Command (AFSOC) and Pacific Air Forces (PACAF). The company was further awarded an Air Force Phase II SBIR to enhance the Contingency Response Mission of Air Mobility Command (AMC) in post-disaster areas.

The company also recently appointed Robert Cardillo to its Board of Directors. Cardillo served as the sixth director of the National Geospatial-Intelligence Agency from 2014 through 2019, where he led the NGA under the authorities of the Secretary of Defense and Director of National Intelligence to transform the Agency’s value proposition through innovative partnerships with the growing commercial geospatial industry.

“Enview’s work with the U.S. Air Force is a testament to the value of scalable, AI-powered processing for 3D geospatial data in mission-critical use cases,” said Cardillo. “I’m excited to witness the innovative ways in which Enview Explore, and future solutions, provide value for not only government organizations, but Fortune 500 companies as well.”

Enview’s geospatial AI platform has been deployed at TRL 9 for Fortune 500 companies for the automated 3D mapping of terrain, buildings, vegetation, infrastructure, route planning, line of sight, change detection, and other bespoke requirements. The platform rapidly generates accurate 3D maps to enhance tactical and theater-level decision-making. Learn more here.

Resources

• 
  Website
  
• 
  Blog
  
• 
  Careers
  
• 
  Twitter
  
• 
  LinkedIn
  
  

About Enview

Enview is pioneering next-generation AI to automatically transform 3D data into insights at unprecedented speed, scale, and detail. Public and private sector organizations use Enview to virtualize the physical world and derive insights to protect people and infrastructure, and enhance national security. For more information and a demo, visit www.enview.com. The company is growing to meet market demand and currently expanding its machine learning and data science teams. Visit www.enview.com/about/careers to learn more.

Media Contact

Tanya Carlsson
Offleash for Enview
(707) 529-6139
[email protected]  

IRONWOOD, Mich., Nov. 16, 2020 (GLOBE NEWSWIRE) — Keweenaw Land Association, Limited (OTC US: KEWL) today announced that its third quarter earnings report is available on its website under “Company Reports” or on the OTC Markets website.

Contact: Paula J. Aijala, Secretary, Keweenaw Land Association, Limited, [email protected]

About Keweenaw Land Association, Limited: Keweenaw is a forest products and land management company located in Ironwood, Michigan. Keweenaw has land holdings exceeding 183,000 surface acres and 400,000 acres of mineral rights, located predominantly in the western Upper Peninsula of Michigan and northern Wisconsin. Additional information is available on the Company’s website at www.keweenaw.com.

Forward-Looking Statements: This release contains forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties and should not be relied upon as predictions of future events or promises of a given course of action. A number of factors such as the ongoing Covid-19 pandemic, changing economic conditions, price fluctuations, land use, environmental and other governmental regulations, and risk of loss from natural disasters, could cause actual results to differ materially from those described in the forward-looking statements. As with any investment, past performance is not a guarantee of future results. The Company is currently not subject to the filing requirements of the Securities Exchange Act of 1934, as amended. The Company is categorized as “Pink Current Information” under the OTC Pink Sheets.

FREMONT, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy management technology company and the world’s leading supplier of microinverter-based solar-plus-storage systems, today announced that it has entered into an agreement with MSpectrum, a solar energy renewable provider with headquarters in Pasig, Philippines, to distribute Enphase products to residential and commercial installers across the Philippines. The Enphase IQ 7™ family of products is expected to be available via MSpectrum starting in the first quarter of 2021.

MSpectrum, the renewable energy division of Manila Electric Company (MERALCO), will distribute the Enphase IQ 7 family of microinverters, which includes IQ 7, IQ 7+™, IQ 7A™, and IQ 7X™, to residential and commercial installers. In addition, the solar systems will be outfitted with Enphase Envoy™ communications gateways, which connect an Enphase-based solar system to the Enphase Enlighten™ software monitoring platform and help make per-panel energy monitoring and insights for operations and maintenance easy.

“We are proud to provide Enphase Energy seventh-generation microinverters in the Philippines,” said Robert Pereja, chief operating officer of MSpectrum. “This next-generation technology will benefit solar customers through its high performance, flexibility, reliability, and most importantly, safety, due to the rapid shutdown device (RSD) built into Enphase microinverters. We aim to work with Enphase to revolutionize the solar industry in the Philippines and motivate more Filipinos to shift from traditional to renewable sources of energy.”

“Enphase’s track record of quality manufacturing, technology, and credibility were some of the major factors for us to join forces with the company,” said Michael Paul Miranda, managing director, 8AM Engineering Services. “As a solar installer in the Philippines, we are pleased that Enphase microinverters have built-in RSD protection, low voltage AC, a simple installation process, and distributed architecture. We look forward to working with Enphase to bring more solar solutions to the Philippines.”

The IQ 7 family of microinverters leverages Enphase’s unique software-defined architecture and semiconductor integration for excellent reliability and economies of scale. Enphase microinverters are subjected to a rigorous reliability and quality testing regimen with more than an aggregated one million hours of cumulative power-on testing to help ensure exceptional performance under heat, high humidity, salty air, and cold. The design is compatible with operating in hot, humid and coastal conditions such as those found in the Philippines.

“We are pleased to join forces with MSpectrum to distribute our products in the Philippines,” said Dave Ranhoff, chief commercial officer at Enphase Energy. “The country’s solar market has great potential for Enphase, particularly in the residential and small commercial rooftop market segment. We believe Enphase’s unique value proposition of high-output performance and flexible installation, as well as a safe low voltage all-AC system architecture and rapid shutdown capability, resonates well in the Philippines solar market.”

To learn more about the Enphase and MSpectrum distribution partnership in the Philippines, please visit MSpectrum’s booth at the virtual Future Energy Show Philippines from Nov. 16-17, 2020, where MSpectrum and Enphase will host Enphase product demonstrations, marking the beginning of the collaboration between Enphase and MSpectrum in the Philippines solar market.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company, delivers smart, easy-to-use solutions that connect solar generation, storage and management on one intelligent platform. The Company revolutionized solar with its microinverter technology and produces the world’s only truly integrated solar plus storage solution. Enphase has shipped more than 30 million microinverters, and approximately 1.3 million Enphase-based systems have been deployed in more than 130 countries. For more information, visit www.enphase.com and follow the company on Facebook, LinkedIn and Twitter.

Enphase Energy, Enphase, the E logo, Enphase Energized, IQ 7, IQ 7+, I 7A, IQ 7X, Envoy, Enlighten, and other trademarks or service names are the trademarks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements


This press release may contain forward-looking statements, including statements related to Enphase Energy’s  availability dates for its products, the expected performance and advantages of its technology and products, including quality, safety, reliability, life expectancy, the simplicity of installation, the ease of monitoring and maintenance, and the ability to future proof and scale systems; anticipated product adoption in the geographies and markets we target; and the capabilities and performance of its partners’ products and services. These forward-looking statements are based on Enphase’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in Enphase’s most recent Annual Report on Form 10-K and other documents on file with the SEC and available on the SEC’s website at www.sec.gov. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Enphase
Energy
Contact:

Robin Yan
General Manager, Emerging Markets
[email protected]
+1 (650) 864-2666

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) — Vital Farms (the “Company) (NASDAQ: VITL), a Certified B Corporation that offers a range of ethically produced pasture-raised foods nationwide, today announced that Russell Diez-Canseco, Chief Executive Officer, and Jason Dale, Chief Financial Officer and Chief Operating Officer, will present at upcoming virtual investor conferences.

Today, Monday, November 16^th, 2020, the Company will host a fireside chat discussion at the Jefferies West Coast Consumer Conference at 11:30 a.m. ET, or 10:30 a.m CT. The discussion can be accessed live at the “Events & Presentations” section of the Vital Farms Investor Relations site at https://investors.vitalfarms.com/investor-relations. The replay will be archived online for 90 days.

Tomorrow, Tuesday, November 17^th, 2020, the Company will participate in a panel discussion on sustainability in the food sector at the Goldman Sachs Sustain Fall Symposium at 9:00 a.m. ET, or 8:00 a.m. CT. For more information, please contact your Goldman Sachs representative.

About Vital Farms

Vital Farms, a Certified B Corporation, offers a range of ethically produced pasture-raised foods nationwide. Started on a single farm in Austin, Texas, in 2007, Vital Farms is the leading U.S. brand of pasture-raised eggs and butter by retail dollar sales. Vital Farms’ ethics are exemplified by its focus on the humane treatment of farm animals and sustainable farming practices. In addition, as a Delaware Public Benefit Corporation, Vital Farms also prioritizes the long-term benefits of each of its stakeholders, including farmers and suppliers, customers and consumers, communities and the environment, and crew members and stockholders. Vital Farms’ pasture-raised products, including shell eggs, butter, hard-boiled eggs, ghee, egg bites and liquid whole eggs, are sold in approximately 16,000 stores nationwide.

Contact

ICR
Ashley DeSimone
[email protected]
646.677.1827